Clinical Trials Sponsored by Orlucent, Inc

Total 35389 results

Orlucent, Inc

Unknown

Skin Fluorescent Imaging (SFI) System in Patients With Nevi

Nevus | Dysplasia; Epithelial

United States
Orlucent, Inc

Enrolling by invitation

INTER-PATHOLOGIST READER STUDY

Nevi, Dysplastic

United States
Orlucent, Inc

Completed

Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)

Skin Lesion | Melanoma (Skin) | Mole

United States
Orlucent, Inc

Completed

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Skin Lesions

Israel
Orlucent, Inc
Clalit Health Services

Completed

Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.

Skin Lesions
Orlucent, Inc
Hadassah Medical Organization

Completed

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Skin Lesion

Israel
Alucent Biomedical

Completed

Natural Vascular Scaffold (NVS) Therapy

Peripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, Peripheral

United States
Alucent Biomedical

Completed

Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)

Peripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, Peripheral

United States
Alucent Biomedical

Recruiting

Alucent Vessel Restoration System for AVF (Activate AVF)

AV Fistula

Australia, Poland
Alucent Biomedical

Active, not recruiting

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: REACTIVATE I (REACTIVATE I)

PAD - Peripheral Arterial Disease

Australia
Alucent Biomedical

Active, not recruiting

Feasibility Study of the Vessel Restoration System (VRS): ACTIVATE II (ACTIVATEII)

PAD - Peripheral Arterial Disease

Australia
AvenCell Europe GmbH
Allucent

Recruiting

Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Germany
MonTa Biosciences ApS
Allucent

Recruiting

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Advanced Solid Tumor

Belgium, Denmark, Spain
Arthritis Innovation Corporation
Allucent

Active, not recruiting

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

Post Operative Pain

United States
Orlucent, Inc
University Hospitals, Leicester; NHS Tayside; University of Dundee; NHS Greater... and other collaborators

Completed

Investigating the Clinical Utility of the MDS (OMS002_UK)

Melanoma | Skin Lesion | Moles

United Kingdom
Biomedical Advanced Research and Development Authority
Rho Federal Systems Division, Inc.; Allucent

Not yet recruiting

Sublingual Atropine Bioequivalence by Route of Administration (SABER) (SABER)

Atropine Bioequivalence

United States
H. Lee Moffitt Cancer Center and Research Institute
Elucent Medical

Completed

Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

Breast Cancer

United States
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
IGC Pharma LLC

Completed

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Dementia of Alzheimer Type

Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
Novan, Inc.
Synteract, Inc.; Therapeutics, Inc.

Completed

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)

Molluscum Contagiosum

United States
OBELAB, Inc.
Helptrial Inc.

Not yet recruiting

Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.

Acute Ischemic Stroke Patients

Korea, Republic of
Athersys, Inc
Medpace, Inc.

Recruiting

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

Ischemic Stroke

United States, Taiwan
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
ModernaTX, Inc.
Aetion, Inc.

Active, not recruiting

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

SARS-CoV-2

United States
Eisai Inc.
Quintiles, Inc.

Terminated

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Australia, Russian Federation, India, Ukraine
AxeroVision, Inc.
ORA, Inc.

Completed

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

Dry Eye

United States
Versartis Inc.

Completed

Long-Acting Growth Hormone in Children Compared to Daily rhGH (VELOCITY)

Growth Disorders
Novan, Inc.
Synteract, Inc.

Completed

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Molluscum Contagiosum

United States
EmitBio Inc.

Completed

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

COVID19

United States
Xoft, Inc.
Icad, Inc.

Withdrawn

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Ductal Carcinoma In Situ | Invasive Ductal Carcinoma
Versartis Inc.

Completed

Versartis Trial in Children to Assess Long-Acting Growth Hormone (VERTICAL)

Pediatric Growth Hormone Deficiency

United States
EmitBio Inc.

Completed

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

COVID19

United States
Mylan Inc.

Completed

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Cystic Fibrosis

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Healios Inc.
Genentech, Inc.

Completed

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

Multiple Sclerosis

United States
Evofem Inc.
Neothetics, Inc

Completed

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Central Abdominal Bulging

United States
Eisai Inc.
Quintiles, Inc.

Terminated

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Advanced or Metastatic Solid Tumors | Previously Untreated Gastric Cancer

United States, Russian Federation, United Kingdom, Ukraine
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States

Clinical Trials Sponsored by Orlucent, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations